autologous GM-K562 vaccine

GM-K562 is an autologous cancer vaccine developed by the Dana-Farber Cancer Institute for the treatment of advanced chronic lymphocytic leukemia (CLL) following reduced-intensity allogeneic stem cell transplantation. The vaccine is a cellular immunotherapy consisting of lethally irradiated autologous CLL tumor cells mixed with K562 cells that have been genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF acts as an immune adjuvant to recruit and activate antigen-presenting cells, which then process and present the patient-specific tumor antigens from the autologous cells to the immune system. This approach aims to enhance the graft-versus-leukemia (GVL) effect and expand leukemia-reactive T cells while minimizing graft-versus-host disease (GVHD). It was evaluated in a Phase 1 clinical trial (NCT00442130) led by Dr. Catherine Wu.

Other names

GM-K562 vaccineGM-K-562 vaccineGM-K 562 vaccineautologous CLL vaccineGM-CSF-secreting K562 bystander cell vaccine